We are currently recruiting for a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants.
The trial is open in Australia and soon to be in the USA. The FDA has approved the U.S. IND (IND 154637) and granted Orphan Drug Designation for SPG302 for the treatment of ALS.
Upcoming U.S. Clinical Trials
NCT05882695 Status: not yet recruiting; please continue to check the status at ClinicalTrials.gov
Location Boston, Massachusetts at Mass General Brigham